UNSPSC 51284122: Cefodizime

This classification denotes a beta-lactam antibacterial with the molecular formula C20H20N6O7S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HC1T51593A, chemically known as (6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(((5-(carboxymethyl)-4-methyl-2-thiazolyl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(z)-(o-methyloxime) but generally known as cefodizime, which bears US NIH Compound Identifier 5361871. Most nations schedule cefodizime under HS 29419000 and SITC 54139.

As of Q4 2014, CEFODIZIME remains the US FDA Preferred Term for this commodity. Cefodizime bears US NLM identifiers UMLS ID C0055007 and NCI Concept Code C98224. SMILES: CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O.

UNSPSC 51284122 Cefodizime is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities tagged under it do not reflect procurement of cefodizime itself. Instead, the code shows activity for other pharmaceutical and medical products — notably naloxone and drug deactivation systems — indicating a significant mismatch between the code's nominal scope and what state and local governments are actually buying under this classification. State and local issuing bodies using this code are sourcing critical care and emergency-response pharmaceuticals through both direct procurement and cooperative purchasing vehicles such as piggyback contracts and inter-governmental consortia.

The recent opportunities reveal activity primarily in Florida and Illinois, with procurement patterns split between competitive sealed bidding and cooperative purchasing arrangements. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with delivery to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2026. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for doxycycline hyclate and ciprofloxacin hydrochloride, totaling $2,999,999.11 over the contract life including renewal options. The code shows little actual activity under its stated pharmaceutical product name; procurement professionals should verify code assignment with state and local issuing bodies before committing resources, as the classification appears to serve as a broad pharmaceutical catch-all rather than a precise product-specific code.